Back

Discussant panel

17 May 2025 (16:00 - 16:00)
Organised by: Logo
Congress Presentation Part of: Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension and valvular heart disease Chronic Heart Failure HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

6 More presentations in this session

Presentation thumbnail
Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: the VELOCITY study
Professor S. Greene (Durham, US)
Slides Video
Presentation thumbnail
Cardiopulmonary exercise testing as a novel endpoint in clinical trials on ATTR amyloid cardiomyopathy
Doctor A. Porcari (London, GB)
Slides Video
Presentation thumbnail
Efficacy and safety of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms
Professor I. Olivotto (Florence, IT)
Slides Video
Presentation thumbnail
Pulmonary artery denervation clinical study using the gradient denervation system in heart failure patients with pulmonary hypertension group 2
Doctor J. Nunez Villota (Valencia, ES)
Slides Video
Presentation thumbnail
Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients.
Doctor A. Muslin (Watertown, US)
Slides Video

Access the full session

Session thumbnail
Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension and valvular heart disease
Video

The Event

Event poster

Heart Failure 2025

17 May 2025 16:00 CET
You may be interested in
thumbnail
Congress Session
Bridging gaps in heart failure care: primary care trends, exercise, kidney function, and global health perspectives
thumbnail
Congress Session
Nursing and Allied Professions Investigator Award
thumbnail
Congress Session
Which device might help your HFpEF patient?

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources